Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Natural Beauty Bio-Technology Limited (0157.HK)
Wan Chai, HK
Natural Beauty Bio-Technology Limited operates as an investment holding company, supplying skincare products and a comprehensive range of services across the People's Republic of China, Taiwan, and other global regions. Under its "Natural Beauty" brand, the firm develops and sells a diverse array of items, including skincare, beauty, aromatherapy goods, cosmetics, health supplements, and makeup. Complementing its product line, the company delivers professional services such as skin treatments, spa and beauty therapies, medical aesthetic procedures, alongside expert consulting and training in skincare and general beauty. Its network of spas further enhances these offerings with hydrotherapy, specialized facial treatments, holistic body care, and detailed skin analysis. Furthermore, the company is involved in the wholesale distribution of its beauty and skincare merchandise. Established in 1976, Natural Beauty Bio-Technology Limited is headquartered in Wan Chai, Hong Kong.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| -1.09% | -2.15% | -4.21% | -9.00% | -9.00% | -7.14% | -9.00% | -12.50% | -30.00% | -53.57% | -24.17% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
| Rating | 2024-11 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 0 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
-
Revenue growth Household & Personal Products: +3.3%+52.4% ★ Q4'25: +57.2% (vs Q4'23)
-
EPS growth Household & Personal Products: +8.8%+110.2% ★ Q4'25: +92.9% (vs Q4'23)
-
FCF margin FCF growth · Household & Personal Products: +44.8%-12.6% Q4'25: -19.6% (vs Q4'23)
-
EBIT margin Household & Personal Products: +9.9%+5.1% Q4'25: +2.2% (vs Q4'23)
-
ROIC Household & Personal Products: +8.2%+3.6% Q4'25: +3.5% (vs Q4'23)
-
Share dilution Household & Personal Products: +0.2%+0.0% Q4'25: +0.0% (vs Q4'23)
-
Debt / EBITDA Net debt/EBITDA · Household & Personal Products: -0.51×5.53× Q4'25: 3.63× (vs Q4'23)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Metric |
Dec 2017 actual |
Dec 2018 actual |
|---|---|---|
| Revenue |
399.58M
est: 577.00M (-30.7%)
|
369.53M
est: 640.00M (-42.3%)
|
| EBITDA |
158.35M
est: 25.31M (+525.7%)
|
61.70M
est: 28.07M (+119.8%)
|
| EBIT |
146.90M
est: -24.70M (+694.7%)
|
37.34M
est: -27.40M (+236.3%)
|
| Net Income |
105.39M
|
26.26M
|
| SGA |
162.40M
est: 352.04M (-53.9%)
|
190.18M
est: 390.48M (-51.3%)
|
| EPS |
0.05
|
0.01
|
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-29 | C+ | 2/5 | 1/5 | 2/5 | 3/5 | 2/5 | 1/5 | 3/5 |
| 2026-05-28 | C+ | 2/5 | 1/5 | 2/5 | 3/5 | 2/5 | 1/5 | 3/5 |
| 2026-05-21 | C+ | 2/5 | 1/5 | 2/5 | 3/5 | 2/5 | 1/5 | 3/5 |
| 2026-05-20 | C+ | 2/5 | 1/5 | 2/5 | 3/5 | 2/5 | 1/5 | 3/5 |
| 2026-05-15 | C+ | 2/5 | 1/5 | 2/5 | 3/5 | 2/5 | 1/5 | 3/5 |
| 2026-05-14 | C+ | 2/5 | 1/5 | 2/5 | 3/5 | 2/5 | 1/5 | 3/5 |
| 2026-05-12 | C+ | 2/5 | 1/5 | 2/5 | 3/5 | 2/5 | 1/5 | 3/5 |
| 2026-05-11 | C+ | 2/5 | 1/5 | 2/5 | 3/5 | 2/5 | 1/5 | 3/5 |
| 2026-05-08 | C+ | 2/5 | 1/5 | 2/5 | 3/5 | 2/5 | 1/5 | 3/5 |
| 2026-05-07 | C+ | 2/5 | 1/5 | 2/5 | 3/5 | 2/5 | 1/5 | 3/5 |
| 2026-05-06 | C+ | 2/5 | 1/5 | 2/5 | 3/5 | 2/5 | 1/5 | 3/5 |
| 2026-05-05 | C+ | 2/5 | 1/5 | 2/5 | 3/5 | 2/5 | 1/5 | 3/5 |
| 2026-05-04 | C+ | 2/5 | 1/5 | 2/5 | 3/5 | 2/5 | 1/5 | 3/5 |
| 2026-04-29 | C | 2/5 | 1/5 | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-24 | C+ | 2/5 | 1/5 | 2/5 | 4/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-23 | C+ | 2/5 | 1/5 | 2/5 | 4/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-20 | C+ | 2/5 | 1/5 | 2/5 | 4/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-16 | C+ | 2/5 | 1/5 | 2/5 | 4/5 | 1/5 | 1/5 | 3/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
This company is not held by any ETF in our universe.
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Chi Chung Cheng | Chief Executive Officer | 4M | male |
| Chien Lei | Executive Chairperson | 1M | — |
| Yen-Ling Lin | Executive Director | 250.0K | female |
| Chia-Wei Lin | Executive Director | 250.0K | male |
| Yen-Yu Tsai | Founder & Honorary Chairman | 83.0K | — |
| Jenny Zhu | Chief Legal Counsel | — | female |
| Mei Yi Lee ACIS FCIS | Company Secretary | — | female |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for 0157.HK
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
